ESC Premium Access

Pulmonary arterial hypertension: risk stratification guides for new treatments and informed outcomes

Event: ESC Congress 2021 - The Digital Experience
Topic: Treatment
Session type: Abstract Sessions
Date: 30 August 2021
Time: 07:15 - 08:00

Congress Session

5 presentations in this session

Non-invasive risk prediction based on right ventricular function in patients with pulmonary arterial hypertension

Speaker: Mrs V. Qaderi (Hamburg, DE)
Thumbnail

Inclusion of echocardiographic measure of right ventricular function in the non-invasive French pulmonary arterial hypertension risk stratification method

Speaker: Doctor C. Fauvel (Rouen, FR)
Thumbnail

Twenty-year experience and outcomes in a national paediatric pulmonary hypertension service

Speaker: Doctor A. Constantine (London, GB)
Thumbnail

Safety, tolerability, and pharmacokinetics (PK) of treprostinil palmitil inhalation powder (TPIP): a phase 1, randomised, double-blind, single- and multiple-dose study

Speaker: Doctor F. Ismat (Bridgewater, US)
Thumbnail

Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis

Speaker: Doctor J. Coghlan (London, GB)
Thumbnail

5 speakers from this session

Mrs Vazhma Qaderi

The University Medical Center Hamburg-Eppendorf, Hamburg (Germany)
0 follower

Doctor Charles Fauvel

University Hospital of Rouen, Rouen (France)
0 follower

Doctor Andrew Constantine

Royal Brompton Hospital, London (United Kingdom of Great Britain & Northern Ireland)
1 follower

Doctor Fraz A Ismat

Insmed Incorporated, Bridgewater (United States of America)
0 follower

Doctor John G Coghlan

Royal Free Hospital, London (United Kingdom of Great Britain & Northern Ireland)
5 presentations
0 follower

This platform is supported by

logo Novo Nordisk